Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23866840 | 0.84 | HSD17B10 (0.69) | CHRM1HSD17B10CYP1A2USP7ALDH1A1 | |
| SCHEMBL16748055 | 0.84 | HSD17B10 (0.69) | CHRM1HSD17B10CYP1A2USP7ALDH1A1 | |
| SCHEMBL17011279 | 0.83 | HSD17B10 (0.52) | CHRM1HSD17B10CYP1A2USP7PPARG | |
| SCHEMBL16748058 | 0.82 | HSD17B10 (0.71) | CHRM1HSD17B10USP7SLC6A2SLC6A4 | |
| SCHEMBL25903271 | 0.82 | HSD17B10 (0.49) | CHRM1HSD17B10SLC6A2SLC6A4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8934375 | 0.81 | HSD17B10 (0.69) | CHRM1HSD17B10USP7SLC6A2SLC6A4 | |
| SCHEMBL6164614 | 0.79 | HDAC8 (0.64) | OPRD1 | |
| SCHEMBL7567649 | 0.79 | HDAC8 (0.64) | OPRD1 | |
| SCHEMBL7566120 | 0.79 | HDAC8 (0.64) | OPRD1 | |
| SCHEMBL16026526 | 0.79 | CYP2C19 (0.47) | OPRD1SIGMAR1HPGDGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108953-B2 | Quinoline derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD7, BRD3 | CHRM1 828/4885HSD17B10 3786/4885CYP1A2 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.